Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 2,601 shares of the company’s stock in a transaction on Friday, February 8th. The stock was sold at an average price of $11.76, for a total transaction of $30,587.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NASDAQ MNTA traded up $0.56 during trading on Monday, hitting $12.76. The company had a trading volume of 554,007 shares, compared to its average volume of 569,954. Momenta Pharmaceuticals, Inc. has a one year low of $9.55 and a one year high of $32.20. The firm has a market capitalization of $1.20 billion, a PE ratio of -10.63 and a beta of 2.04.

MNTA has been the subject of several research reports. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Thursday, January 3rd. ValuEngine lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 27th. Piper Jaffray Companies initiated coverage on shares of Momenta Pharmaceuticals in a report on Monday, November 5th. They issued an “overweight” rating and a $35.00 price objective for the company. Stifel Nicolaus set a $39.00 price objective on shares of Momenta Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. Finally, BidaskClub lowered shares of Momenta Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, January 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $25.75.

Hedge funds and other institutional investors have recently modified their holdings of the business. Oregon Public Employees Retirement Fund purchased a new stake in shares of Momenta Pharmaceuticals in the 4th quarter worth about $37,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Momenta Pharmaceuticals by 41.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,880 shares of the biotechnology company’s stock worth $65,000 after buying an additional 1,723 shares during the period. Smith Asset Management Group LP purchased a new stake in shares of Momenta Pharmaceuticals in the 4th quarter worth about $99,000. Fox Run Management L.L.C. purchased a new stake in shares of Momenta Pharmaceuticals in the 4th quarter worth about $143,000. Finally, Sawtooth Solutions LLC purchased a new stake in shares of Momenta Pharmaceuticals in the 3rd quarter worth about $227,000. Institutional investors and hedge funds own 76.86% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 2,601 Shares” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2019/02/11/momenta-pharmaceuticals-inc-mnta-ceo-craig-a-wheeler-sells-2601-shares.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Featured Story: Why is the conference call important?

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.